Seema Nair, MD
Neurology · Burlingame
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 2
Offices
2 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Nair’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A119685 · Current
Licensed to practise in California · since 2012 · expires 2027-07-31 · Calicut University Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$69,259
Medicare paid this office $69,259 for 205 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 71 | $17,989 | $162 |
| Critical care, first 30-74 minutes | 26 | $10,655 | $178 |
| Return visit (30+ min) | 57 | $7,955 | $112 |
| Short return visit (20+ min) | 59 | $5,988 | $76 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $4,636 | $105 |
See all 12 services
| Long return visit (40+ min) | 71 | $17,989 | $162 |
| Critical care, first 30-74 minutes | 26 | $10,655 | $178 |
| Return visit (30+ min) | 57 | $7,955 | $112 |
| Short return visit (20+ min) | 59 | $5,988 | $76 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $4,636 | $105 |
| New patient visit (60+ min) | 19 | $3,688 | $194 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 134 | $3,458 | $14 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,311 | $154 |
| New patient visit (45+ min) | 13 | $1,984 | $153 |
| Critical care, each additional 30 minutes | 13 | $1,661 | $92 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 29 | $979 | $29 |
| Short return visit | 13 | $587 | $45 |
Who their Medicare patients are
205 Original Medicare patients in 2024. Average age 77 · Under 65 6% · 85 and older 22% · Women 61% · Also on Medicaid 15% · Health risk score 1.37. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 73% · Diabetes 31% · Depression 30% · Chronic kidney disease 28% · Coronary heart disease 26% · Dementia 25% · Stroke 23% · Atrial fibrillation 21% · Heart failure 17% · Cancer 13% · COPD 10%.
The office billed $265,563, Medicare allowed $91,869 and paid $69,259; for 1,934 services of 20 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 205 | 1,934 | 77 | 1.37 | $265,563 | $69,259 |
| 2023 | 189 | 984 | 78 | 1.24 | $172,453 | $48,871 |
| 2022 | 200 | 425 | 77 | 1.34 | $189,859 | $53,605 |
| 2021 | 202 | 600 | 77 | 1.14 | $180,929 | $52,436 |
| 2020 | 165 | 301 | 78 | 1.24 | $129,973 | $36,491 |
| 2019 | 242 | 473 | 77 | 1.51 | $211,380 | $59,496 |
| 2018 | 286 | 733 | 77 | 1.50 | $234,441 | $66,137 |
| 2017 | 201 | 1,007 | 77 | 1.33 | $189,530 | $55,028 |
| 2016 | 146 | 398 | 76 | 1.42 | $81,727 | $23,222 |
| 2015 | 274 | 4,392 | 66 | 1.51 | $308,275 | $113,728 |
| 2014 | 285 | 7,059 | 57 | 1.68 | $406,389 | $142,750 |
| 2013 | 244 | 1,340 | 61 | 2.21 | $112,285 | $43,554 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Long return visit (40+ min) | 73 | $15,228 | $155 |
| Return visit (30+ min) | 63 | $7,857 | $108 |
| Critical care, first 30-74 minutes | 11 | $3,979 | $189 |
| New patient visit (60+ min) | 21 | $3,958 | $188 |
| Short return visit (20+ min) | 45 | $3,705 | $76 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $2,914 | $108 |
| New patient visit (45+ min) | 16 | $2,349 | $147 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,203 | $157 |
| Short return visit | 17 | $916 | $54 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 20 | $622 | $30 |
2022: 9 services
| Long return visit (40+ min) | 68 | $14,930 | $157 |
| Return visit (30+ min) | 65 | $9,184 | $112 |
| New patient visit (60+ min) | 40 | $8,037 | $201 |
| Critical care, first 30-74 minutes | 14 | $6,508 | $181 |
| New patient visit (45+ min) | 25 | $3,684 | $147 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $3,577 | $92 |
| Short return visit (20+ min) | 37 | $2,971 | $78 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 22 | $822 | $29 |
| Short return visit | 11 | $651 | $54 |
2021: 8 services
| New patient visit (60+ min) | 58 | $11,844 | $204 |
| Long return visit (40+ min) | 51 | $11,338 | $155 |
| Return visit (30+ min) | 50 | $6,048 | $103 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $3,922 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,520 | $168 |
| New patient visit (45+ min) | 22 | $3,280 | $149 |
| Short return visit (20+ min) | 35 | $2,783 | $70 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 20 | $700 | $30 |
2020: 7 services
| Long return visit (40+ min) | 48 | $7,570 | $120 |
| New patient visit (60+ min) | 37 | $6,325 | $171 |
| Return visit (30+ min) | 45 | $5,197 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $3,342 | $95 |
| New patient visit (45+ min) | 19 | $2,570 | $135 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,165 | $144 |
| Short return visit (20+ min) | 20 | $1,523 | $73 |
2019: 8 services
| Long return visit (40+ min) | 63 | $10,621 | $128 |
| New patient visit (60+ min) | 56 | $10,410 | $186 |
| Return visit (30+ min) | 82 | $9,667 | $97 |
| Critical care, first 30-74 minutes | 22 | $7,620 | $195 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 53 | $7,443 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $6,245 | $173 |
| New patient visit (45+ min) | 31 | $4,149 | $134 |
| Short return visit (20+ min) | 20 | $1,489 | $65 |
2018: 9 services
| Long return visit (40+ min) | 77 | $11,359 | $122 |
| Return visit (30+ min) | 88 | $9,668 | $92 |
| New patient visit (60+ min) | 53 | $9,415 | $178 |
| Critical care, first 30-74 minutes | 30 | $8,939 | $190 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 65 | $8,750 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 48 | $8,433 | $176 |
| New patient visit (45+ min) | 32 | $4,606 | $144 |
| Short return visit (20+ min) | 21 | $1,436 | $68 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,035 | $65 |
2017: 8 services
| Critical care, first 30-74 minutes | 30 | $9,312 | $190 |
| New patient visit (60+ min) | 50 | $9,166 | $183 |
| Long return visit (40+ min) | 44 | $8,180 | $132 |
| Return visit (30+ min) | 58 | $7,491 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 47 | $5,716 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $5,591 | $180 |
| New patient visit (45+ min) | 18 | $2,640 | $147 |
| Short return visit (20+ min) | 16 | $1,034 | $65 |
2016: 6 services
| New patient visit (45+ min) | 34 | $4,710 | $139 |
| Return visit (30+ min) | 48 | $4,653 | $86 |
| New patient visit (60+ min) | 13 | $2,155 | $166 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $2,108 | $117 |
| Long return visit (40+ min) | 15 | $1,883 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,135 | $63 |
2015: 15 services
| Return visit (30+ min) | 96 | $9,360 | $88 |
| New patient visit (60+ min) | 28 | $5,519 | $197 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 34 | $4,937 | $55 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 47 | $4,793 | $54 |
| New patient visit (45+ min) | 32 | $4,478 | $140 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 45 | $3,738 | $15 |
| Injection of additional new drug or substance into vein | 36 | $3,106 | $18 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $2,712 | $97 |
| Unclassified drugs | 28 | $505 | None |
| Electrocardiogram (ecg) 1 to 3 leads | 36 | $258 | $5 |
| Injection, ondansetron hydrochloride, per 1 mg | 33 | $24 | None |
| Injection, ketorolac tromethamine, per 15 mg | 22 | $20 | None |
| Injection, midazolam hydrochloride, per 1 mg | 28 | $17 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 21 | $13 | None |
| Injection, metoclopramide hcl, up to 10 mg | 16 | $10 | None |
2014: 15 services
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 106 | $13,166 | $57 |
| Return visit (30+ min) | 96 | $11,217 | $80 |
| Injection of additional new drug or substance into vein | 82 | $9,669 | $18 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 104 | $9,535 | $15 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 39 | $5,182 | $59 |
| New patient visit (45+ min) | 28 | $3,849 | $137 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 26 | $3,099 | $115 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,848 | $154 |
| Electrocardiogram (ecg) 1 to 3 leads | 81 | $828 | $5 |
| Unclassified drugs | 61 | $268 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 75 | $78 | None |
| Injection, ketorolac tromethamine, per 15 mg | 68 | $68 | None |
| Injection, midazolam hydrochloride, per 1 mg | 60 | $48 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 47 | $32 | None |
| Injection, metoclopramide hcl, up to 10 mg | 30 | $26 | None |
2013: 15 services
| Return visit (30+ min) | 112 | $11,164 | $76 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $2,577 | $92 |
| New patient visit (45+ min) | 19 | $2,537 | $134 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 33 | $2,361 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $2,282 | $56 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 33 | $1,848 | $18 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,695 | $154 |
| Injection of additional new drug or substance into vein | 26 | $1,561 | $19 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 19 | $1,494 | $79 |
| Electrocardiogram (ecg) 1 to 3 leads | 28 | $164 | $5 |
| Injection, ketorolac tromethamine, per 15 mg | 18 | $21 | None |
| Unclassified drugs | 19 | $16 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 22 | $16 | None |
| Injection, midazolam hydrochloride, per 1 mg | 16 | $8 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 11 | $6 | None |
Drugs they prescribed that Part D paid
$57,190
Pharmacies billed $57,190 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
992 generic and fewer than 11 brand-name prescriptions · $57,190 in drug cost · 45 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rytary | Parkinson's | 16 | $13,685 | $855 |
| Levetiracetam | None | 76 | $2,639 | $35 |
| Gabapentin | None | 248 | $2,536 | $10 |
| Memantine | None | 86 | $2,002 | $23 |
| Donepezil | None | 153 | $1,404 | $9 |
See all 22 drugs
| Rytary | Parkinson's | 16 | $13,685 | $855 |
| Levetiracetam | None | 76 | $2,639 | $35 |
| Gabapentin | None | 248 | $2,536 | $10 |
| Memantine | None | 86 | $2,002 | $23 |
| Donepezil | None | 153 | $1,404 | $9 |
| Carbidopa-Levodopa | None | 55 | $1,272 | $23 |
| Lacosamide | None | 35 | $1,233 | $35 |
| Pregabalin | None | 13 | $1,107 | $85 |
| Carbamazepine | None | 11 | $695 | $63 |
| Rizatriptan | None | 14 | $617 | $44 |
| Rivastigmine | None | 13 | $593 | $46 |
| Divalproex Sodium Er | None | 13 | $592 | $46 |
| Levetiracetam Er | None | 19 | $531 | $28 |
| Nortriptyline | None | 28 | $466 | $17 |
| Propranolol | None | 12 | $362 | $30 |
| Olanzapine | None | 13 | $339 | $26 |
| Zonisamide | None | 11 | $313 | $28 |
| Primidone | None | 13 | $277 | $21 |
| Quetiapine | None | 31 | $233 | $8 |
| Atorvastatin | None | 16 | $196 | $12 |
| Topiramate | None | 12 | $71 | $6 |
| Citalopram Hbr | None | 22 | $35 | $2 |
Year by year
| 2024 | 1,033 | 180 | None | None | $57,190 |
| 2023 | 863 | 171 | 0% (0) | 5% | $59,860 |
| 2022 | 701 | 139 | None | 7% | $68,669 |
| 2021 | 599 | 135 | None | 7% | $115,554 |
| 2020 | 529 | 115 | None | None | $37,701 |
| 2019 | 727 | 176 | None | 7% | $148,952 |
| 2018 | 634 | 172 | 2% (14) | 5% | $48,551 |
| 2017 | 370 | 107 | 5% (18) | 4% | $14,957 |
| 2016 | 431 | 130 | 5% (20) | None | $18,471 |
| 2015 | 467 | 115 | 6% (28) | None | $33,578 |
| 2014 | 460 | 81 | 4% (20) | 10% | $64,347 |
| 2013 | 435 | 71 | 4% (16) | 19% | $37,769 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Eliquis | None | 17 | $10,745 | $632 |
| Aimovig | Migraine | 11 | $8,769 | $797 |
| Lacosamide | None | 21 | $2,655 | $126 |
| Donepezil | None | 107 | $2,549 | $24 |
| Gabapentin | None | 229 | $2,501 | $11 |
| Carbidopa-Levodopa | None | 91 | $2,444 | $27 |
| Levetiracetam | None | 82 | $2,218 | $27 |
| Memantine | None | 44 | $1,756 | $40 |
| Carbamazepine | None | 20 | $1,209 | $60 |
| Divalproex Sodium Er | None | 11 | $1,002 | $91 |
| Levetiracetam Er | None | 19 | $798 | $42 |
| Carbidopa-Levodopa Er | None | 17 | $711 | $42 |
| Nortriptyline | None | 23 | $417 | $18 |
| Duloxetine | None | 19 | $183 | $10 |
| Quetiapine | None | 13 | $178 | $14 |
| Topiramate | None | 17 | $170 | $10 |
| Citalopram Hbr | None | 15 | $44 | $3 |
2022: 10 drugs
| Eliquis | 22 | $12,489 | $568 |
| Divalproex Sodium Er | 12 | $5,475 | $456 |
| Gabapentin | 211 | $3,844 | $18 |
| Carbidopa-Levodopa | 86 | $2,436 | $28 |
| Donepezil | 98 | $1,910 | $19 |
| Levetiracetam | 53 | $1,490 | $28 |
| Memantine | 27 | $1,284 | $48 |
| Dilantin | 14 | $658 | $47 |
| Nortriptyline | 23 | $554 | $24 |
| Atorvastatin | 13 | $107 | $8 |
2021: 10 drugs
| Eliquis | 13 | $7,964 | $613 |
| Divalproex Sodium Er | 12 | $5,170 | $431 |
| Gabapentin | 193 | $2,451 | $13 |
| Levetiracetam | 38 | $1,400 | $37 |
| Donepezil | 86 | $1,012 | $12 |
| Carbidopa-Levodopa | 41 | $1,003 | $24 |
| Memantine | 17 | $699 | $41 |
| Dilantin | 16 | $643 | $40 |
| Nortriptyline | 18 | $182 | $10 |
| Citalopram Hbr | 12 | $66 | $5 |
2020: 9 drugs
| Eliquis | 15 | $8,273 | $552 |
| Gabapentin | 167 | $2,130 | $13 |
| Carbidopa-Levodopa | 50 | $1,545 | $31 |
| Levetiracetam | 58 | $1,290 | $22 |
| Memantine | 22 | $808 | $37 |
| Donepezil | 52 | $766 | $15 |
| Phenytoin Sodium Extended | 11 | $309 | $28 |
| Nortriptyline | 12 | $200 | $17 |
| Atorvastatin | 12 | $38 | $3 |
2019: 14 drugs
| Tecfidera | 12 | $101,209 | $8,434 |
| Gabapentin | 189 | $3,358 | $18 |
| Carbidopa-Levodopa Er | 21 | $1,433 | $68 |
| Levetiracetam | 55 | $1,284 | $23 |
| Memantine | 24 | $1,268 | $53 |
| Carbidopa-Levodopa | 45 | $999 | $22 |
| Donepezil | 82 | $903 | $11 |
| Nortriptyline | 24 | $386 | $16 |
| Phenytoin Sodium Extended | 12 | $324 | $27 |
| Clopidogrel | 25 | $300 | $12 |
| Atorvastatin | 33 | $262 | $8 |
| Primidone | 11 | $223 | $20 |
| Topiramate | 14 | $110 | $8 |
| Citalopram Hbr | 12 | $59 | $5 |
2018: 11 drugs
| Gabapentin | 117 | $2,551 | $22 |
| Carbidopa-Levodopa | 65 | $1,334 | $21 |
| Memantine | 22 | $1,245 | $57 |
| Levetiracetam | 31 | $852 | $27 |
| Donepezil | 75 | $698 | $9 |
| Nortriptyline | 38 | $473 | $12 |
| Clopidogrel | 21 | $418 | $20 |
| Divalproex | 11 | $396 | $36 |
| Atorvastatin | 28 | $309 | $11 |
| Citalopram Hbr | 23 | $105 | $5 |
| Pramipexole Dihydrochloride | 14 | $72 | $5 |
2017: 8 drugs
| Gabapentin | 120 | $1,644 | $14 |
| Memantine | 16 | $1,387 | $87 |
| Carbidopa-Levodopa | 29 | $772 | $27 |
| Donepezil | 37 | $432 | $12 |
| Levetiracetam | 11 | $358 | $33 |
| Divalproex | 11 | $249 | $23 |
| Nortriptyline | 16 | $143 | $9 |
| Citalopram Hbr | 11 | $29 | $3 |
2016: 8 drugs
| Gabapentin | 116 | $1,369 | $12 |
| Memantine | 12 | $999 | $83 |
| Carbidopa-Levodopa | 33 | $805 | $24 |
| Donepezil | 73 | $724 | $10 |
| Levetiracetam | 22 | $416 | $19 |
| Hydrocodone-Acetaminophen | 12 | $165 | $14 |
| Nortriptyline | 11 | $159 | $14 |
| Sertraline | 12 | $78 | $6 |
2015: 11 drugs
| Lyrica | 19 | $8,852 | $466 |
| Protriptyline | 14 | $2,245 | $160 |
| Gabapentin | 127 | $2,224 | $18 |
| Levetiracetam | 23 | $1,315 | $57 |
| Carbidopa-Levodopa | 21 | $579 | $28 |
| Tramadol | 25 | $523 | $21 |
| Donepezil | 26 | $346 | $13 |
| Losartan-Hydrochlorothiazide | 12 | $311 | $26 |
| Clopidogrel | 11 | $272 | $25 |
| Clonazepam | 19 | $135 | $7 |
| Cyclobenzaprine | 14 | $106 | $8 |
2014: 11 drugs
| Gabapentin | 111 | $2,069 | $19 |
| Levetiracetam | 24 | $1,539 | $64 |
| Clopidogrel | 20 | $674 | $34 |
| Carbidopa-Levodopa | 15 | $409 | $27 |
| Tramadol | 16 | $350 | $22 |
| Pramipexole Dihydrochloride | 11 | $267 | $24 |
| Nortriptyline | 15 | $106 | $7 |
| Clonazepam | 11 | $79 | $7 |
| Donepezil | 12 | $67 | $6 |
| Prednisone | 13 | $59 | $5 |
| Topiramate | 12 | $56 | $5 |
2013: 12 drugs
| Lyrica | 35 | $7,349 | $210 |
| Vimpat | 11 | $3,611 | $328 |
| Cymbalta | 13 | $2,749 | $211 |
| Levetiracetam | 39 | $2,102 | $54 |
| Gabapentin | 77 | $1,793 | $23 |
| Topiramate | 46 | $696 | $15 |
| Carbamazepine Xr | 12 | $669 | $56 |
| Clopidogrel | 15 | $591 | $39 |
| Metoclopramide | 15 | $152 | $10 |
| Baclofen | 12 | $67 | $6 |
| Prednisone | 12 | $56 | $5 |
| Nortriptyline | 15 | $50 | $3 |
Money from drug and device companies
$12 in 2022
| 2022 | 1 | 1 | None | $12 |
| 2019 | 1 | 1 | None | $27 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Impel Pharmaceuticals | Trudhesa | $12 | 1 payment
|
See the published payment
| Impel Pharmaceuticals | Education · 2022-08-25 | Trudhesa | $12 |
See earlier years (2019)
2019: $27
| Amgen | Aimovig | $27 | 1 payment
|
Professional record
- NPI
- 1538329743
- Licence
- CA A119685California A119685: Current · expires 2027-07-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2008-06-11
- NPI last updated
- 2020-06-22
- NPI record certified
- 2020-06-22
This is when the NPI record was last certified, not a medical board exam.